Conba Pharma to cancel repurchased shares, reduce capital

Zhejiang Conba Pharmaceutical (SSE:600572) announced its plan to cancel 63,579,048 repurchased shares, representing 2.46% of the company's total share capital. This move will reduce the total share capital from 2,584,735,109 shares to 2,521,156,061 shares, and the registered capital will correspondingly decrease from CNY 2,584,735,109 to CNY 2,521,156,061. The shares were initially repurchased for a potential equity incentive plan between January and July 2024 at an average price of CNY 4.72 per share, totaling CNY 29,992,410.00. Creditors are notified to claim their rights within 45 days from the announcement date.